Arrowsmith Edward - Tennessee Oncol PLLC, Sarah Cannon Res Inst

基本信息

浏览量：48

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 62 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

A Phase 2 Study of AZD4635 in Combination with Durvalumab or Oleclumab in Patients with Metastatic Castration-Resistant Prostate Cancer

Gerald S. Falchook,James Reeves, Sunil Gandhi,David R. Spigel,Edward Arrowsmith,Daniel J. George,Janet Karlix,Gayle Pouliot,Maureen M. Hattersley,Eric T. Gangl,Gareth D. James, Jeff Thompson,Deanna L. Russell, Bhavickumar Patel,Rakesh Kumar,Emerson Lim

CANCER IMMUNOLOGY IMMUNOTHERAPYno. 4 (2024)

引用0浏览0WOS引用

599 Single-agent safety and activities of target-preserving anti-CTLA-4 antibody gotistobart (ONC-392/BNT316) in PD-(L)1 resistant metastatic NSCLC and population PK analysis in patients with solid tumors

Journal for ImmunoTherapy of Cancerno. Suppl 1 (2023)

引用0浏览0引用

Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors

JAMA Oncologyno. 1 (2023): 29-29

引用0浏览0引用

Clinical Value of Timely Targeted Therapy (TT) for Patients with Advanced Non-Small Cell Lung Cancer (ansclc) with Actionable Driver Oncogenes (ADO)

Thomas Stricker,Neha Jain,Elaine Yu,Esprit Ma,Robert Schuldt,Rongrong Wang,Jesse Sussell,Sarika Ogale,Tania Szado,Richard Price,Victor T. G. Lin,Dennis Slater,Daniel A. Vaena,Harry Staszewski,Bruno Fang,Lasika Seneviratne,Edward Arrowsmith,Davey B. Daniel

Journal of Clinical Oncologyno. 16_suppl (2023): 6507-6507

引用0浏览0引用

Provider Messaging for Precision Treatment (prompt): A Notification Pilot Study to Inform Actionable Genomic Findings

Neha Jain, Curtis Schunk,Joseph Y. Abrams,Edward Arrowsmith,Garrett Young,Davey B. Daniel,Thomas Stricker

JCO oncology practiceno. 11_suppl (2023): 448-448

引用0浏览0引用

Belzutifan Plus Cabozantinib for Patients with Advanced Clear Cell Renal Cell Carcinoma Previously Treated with Immunotherapy: an Open-Label, Single-Arm, Phase 2 Study

Toni K. Choueiri,David F. McDermott,Jaime Merchan, Todd M. Bauer,Robert Figlin,Elisabeth Heath,M. Dror Michaelson,Edward Arrowsmith,Anishka D'Souza, Song Zhao,Ananya Roy,Rodolfo Perini,Donna Vickery,Scott S. Tykodi

The Lancet Oncologyno. 5 (2023): 553-562

引用16浏览0WOS引用

Abstract 933: Real world treatment patterns and outcomes in patients with advanced non-small cell lung cancer (aNSCLC) post-EGFR tyrosine kinase inhibitor (TKI) therapy

Ericka Ebot, Jie He, David Fabrizio,Ivy Altomare, Nidhi Jain,Davey B. Daniel,Thomas Stricker,Edward Arrowsmith

Cancer Researchno. 7_Supplement (2023): 933-933

引用0浏览0引用

Safety and Clinical Activity of Target-Preserving Anti-Ctla-4 Antibody ONC-392 As Monotherapy in NSCLC Patients Who Progressed on PD(L)1-targeted Immunotherapy

Kai He,David Paul Carbone,Meredith McKean,Rama Balaraman,Satish Shah,Edward Arrowsmith,Julio Antonio Peguero,Rohit Joshi,Aiwu Ruth He, Adriana Milillo,John Turner Hamm,Mark Gregory Goldstein,Zihai Li,Yang Liu,Pan Zheng,Tianhong Li

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023)

引用0浏览0引用

Ezabenlimab (BI 754091), an anti-PD-1 antibody, in combination with BI 836880, a VEGF/Ang2-blocking nanobody, in patients (pts) with advanced colorectal cancer (CRC)

Susanna Varkey Ulahannan,Ivor John Percent,Edward Arrowsmith,Maen A. Hussein, Viralkumar K. Bhanderi,John Hamm,Greg Andrew Durm,Damijan Erzen, Prasant Mohanty,David R. Spigel

Journal of Clinical Oncologyno. 4_suppl (2022): 98-98

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn